From One-Size-Fits-All to Precision Prescribing
Every clinician has experienced it: two patients receive the same medication at the same dose, yet one responds well while the other suffers an adverse reaction. For much of medical history, this variability was attributed to vague concepts like "individual differences." Today, pharmacogenomics offers a scientific explanation — and a path toward genuinely personalized therapy.
Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs. By identifying genetic variants that affect drug metabolism, transport, and target receptors, clinicians can predict which patients will benefit, which will not respond, and which face elevated risk of toxicity.
How Genes Influence Drug Response
Genetic variation affects drug response through several mechanisms:
- Drug Metabolism (Pharmacokinetics): Enzymes such as those in the cytochrome P450 (CYP) family metabolize the majority of clinically used drugs. Variants in genes like CYP2D6, CYP2C19, and CYP3A4/5 classify individuals as poor, intermediate, normal, or ultra-rapid metabolizers — directly affecting drug plasma levels and efficacy.
- Drug Transporters: Genes such as SLCO1B1 affect how drugs are transported into and out of cells (e.g., simvastatin-related myopathy risk).
- Drug Targets: Variants in receptor genes can alter how a target responds to a drug (e.g., beta-blocker response and ADRB1 polymorphisms).
- Immune Reactions: Certain HLA alleles predict severe hypersensitivity reactions — a well-known example is the association between HLA-B*57:01 and abacavir hypersensitivity in HIV treatment.
Clinical Applications Today
| Gene | Drug(s) Affected | Clinical Implication |
|---|---|---|
| CYP2D6 | Codeine, tamoxifen, antidepressants | Dosing adjustment or drug avoidance |
| CYP2C19 | Clopidogrel, proton pump inhibitors | Antiplatelet efficacy variability |
| TPMT / NUDT15 | Thiopurines (azathioprine, 6-MP) | Risk of severe myelosuppression |
| HLA-B*57:01 | Abacavir | Screen before prescribing; avoid if positive |
| SLCO1B1 | Statins | Myopathy risk at standard doses |
Barriers to Widespread Adoption
Despite its promise, pharmacogenomics has not yet become routine in most clinical settings. Key barriers include:
- Cost and Access: Genetic testing costs are declining but remain a barrier in resource-limited settings.
- Clinical Decision Support: Interpreting genetic data requires integrated tools within electronic health records.
- Education Gap: Many practicing clinicians received limited training in genomics and may feel uncertain interpreting results.
- Diverse Population Data: Most pharmacogenomic databases are built predominantly from European ancestry populations, limiting generalizability.
The Road Ahead
As sequencing costs continue to fall and health systems invest in genomic infrastructure, preemptive pharmacogenomic testing — ordering panels before a patient ever needs a specific drug — is becoming feasible. Health science professionals who develop fluency in this field will be better equipped to participate in the precision medicine revolution and deliver safer, more effective care to their patients.